BIAF — bioAffinity Technologies, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1712762 ·
Last close
$5.64
Market Cap
$3.39M
52W High
$80.70
52W Low
$4.56
ADV30
7,404,411
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 1,351,527 | 422,891 | -3,616,976 | -3,630,610 | 7,945,252 | 3,098,366 | 4,283,866 |
| Dec 2025 | 1,538,813 | 638,687 | -3,190,963 | -3,137,466 | 10,960,772 | 6,449,782 | 3,683,116 |
| Sep 2025 | 1,446,066 | 503,855 | -2,292,846 | -5,051,084 | 11,546,369 | 7,669,195 | 2,644,171 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,914,307
Investing CF
$-15,445
Financing CF
$13,583,412
CapEx
$-69,877
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-15.45
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,184,674
Inventory
$77,887
Receivables
$685,235
ST Investments
—
EBIT TTM
$-15,800,991
Pretax Income TTM
$-15,844,600
Interest Exp TTM
$43,609
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,900,985
EBITDA
$-11,968,556
Free Cash Flow
$-6,909,285
Enterprise Value
$3,297,158
Total Cash
$2,429,719
Total Debt
$1,435,005
Shares Out
600,736
Trailing EPS
$-1.35
Book Value
$8.34
ROE
-1860.2%
ROA
-125.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,107,959 | -10,626,508 | -14,909,754 | 10,960,772 | 3,683,116 | 7,277,656 | -9,328,842 |
| Dec 2024 | 9,362,022 | -8,953,445 | -9,039,831 | 6,513,667 | 3,911,631 | 2,602,036 | -7,264,795 |
| Dec 2023 | 2,532,499 | -7,973,228 | -7,937,011 | 8,221,552 | 3,366,297 | 4,855,255 | -6,037,806 |
| Dec 2022 | 4,803 | -4,011,058 | -8,154,113 | 12,182,125 | 1,138,682 | 11,043,443 | -4,070,845 |
TTM Snapshot
Revenues TTM
$5,659,889
NetIncome TTM
$-15,879,947
OpCashFlow TTM
—
Assets (Latest)
$7,945,252
Forward EPS
$-0.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BUDZ | WEED, INC. | $3.38M | $0.02 | — |
| NYMXF | NYMOX PHARMACEUTICAL CORP | $3.36M | $0.03 | — |
| VNRX | VOLITIONRX LTD | $4.15M | $0.22 | — |
| ISPC | iSpecimen Inc. | $2.75M | $1.09 | — |
| TRIB | TRINITY BIOTECH PLC | $4.91M | $6.04 | — |
News headlines (Yahoo Finance, 1h cache)
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-09 16:30 · Yahoo
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-09 15:37 · Yahoo
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-08 17:30 · Yahoo
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-10-08 16:07 · Yahoo
bioAffinity Technologies Receives Japanese Patent Allowance for CyPath Lung AI Diagnostic Test
2026-10-08 14:34 · Yahoo
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
2026-10-06 13:19 · Yahoo
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
2026-09-30 12:00 · Yahoo
bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection
2026-09-28 09:17 · Yahoo
bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference
2026-09-22 14:41 · Yahoo
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
2026-09-22 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.